C
Cezary Szczylik
Researcher at Medical University of Warsaw
Publications - 291
Citations - 30393
Cezary Szczylik is an academic researcher from Medical University of Warsaw. The author has contributed to research in topics: Renal cell carcinoma & Cancer. The author has an hindex of 49, co-authored 274 publications receiving 27380 citations. Previous affiliations of Cezary Szczylik include Military Medical Academy & Cora.
Papers
More filters
Journal ArticleDOI
Culture in embryonic kidney serum and xeno-free media as renal cell carcinoma and renal cell carcinoma cancer stem cells research model.
Krzysztof M. Krawczyk,Damian Matak,Lukasz Szymanski,Cezary Szczylik,Camillo Porta,Anna M. Czarnecka +5 more
TL;DR: Developing a renal carcinoma serum free culture model optimized for (embryonal) renal cells in order to select the best study model for downstream auto-, para- or endocrine research revealed that xeno-free embryonal renal cells optimized culture media provide a useful tool in RCC cancer biology research and at the same time enable effective growth of RCC.
Journal ArticleDOI
Open-Label Phase II Trial of First-Line Everolimus Monotherapy in Patients with Advanced Papillary Renal Cell Carcinoma: Raptor Interim Analysis
Bernard Escudier,Sergio Bracarda,J. P. Maroto,Cezary Szczylik,Paul Nathan,Sylvie Negrier,K. Slimane,C. May,C. Porta,Viktor Grünwald +9 more
TL;DR: Results of this interim analysis have demonstrated that everolimus provides clinical benefit to patients with advanced papillary RCC, and support the further evaluation ofEverolimus as a first-line treatment option for patients withadvanced papillaryRCC.
Journal ArticleDOI
Cardiac safety of systemic therapy in breast cancer patients with high risk of atherosclerosis complications
Arthur Matyszewski,Anna M. Czarnecka,Paweł Stachowiak,Marta Nowakowska,Zdzisława Kornacewicz-Jach,Jarosław D. Kasprzak,Cezary Szczylik +6 more
TL;DR: Use of potentially cardiotoxic chemo regimens in breast cancer patients with cardiac comorbidities, with optimized cardiac therapy accordingly can save patients from development of early myocardial dysfunction induced by chemotherapy.
Journal ArticleDOI
The impact of oophorectomy on survival from breast cancer in patients with CHEK2 mutations
Joanna Tomiczek-Szwiec,Marek Szwiec,M. De Falco,Cezary Cybulski,Dominika Wokołorczyk,Anna Jakubowska,Jacek Gronwald,Małgorzata Stawicka,Dariusz Godlewski,E. Kilar,E. Marczyk,Monika Siołek,Rafal Wisniowski,Olga Haus,R. Sibilski,Lubomir Bodnar,Ping Sun,Steven A. Narod,Jan Lubinski,Tomasz Huzarski,Maria Blasinska-Morawiec,Maria Chosia,K Drosik,S. Gozdecka-Grodecka,Stanisław Góźdź,Ewa Grzybowska,Arkadiusz Jeziorski,Aldona Karczewska,Radzisaw Kordek,Agnieszka Synowiec,Beata Kozak-Klonowska,Katarzyna Lamperska,Dariusz Lange,Andrzej Mackiewicz,Jacqueline Mitus,S Niepsuj,Oleg Oszurek,K. Gugała,Zbigniew Morawiec,T Mierzwa,M Posmyk,Jan Ryś,Cezary Szczylik,Michal Ucinski,K. Urbański,Bernard Waśko,P. Wandzel +46 more
TL;DR: In this article , the authors estimate the impact of oophorectomy and other treatments on the survival of breast cancer patients with a CHEK2 mutation using the Cox proportional hazards model.
Journal ArticleDOI
Optimal chemotherapy treatment for patients with advanced colorectal cancer
TL;DR: This article contains a review of randomized phase II/III studies and registration trials regarding systemic treatment of CRC and has attempted to translate the results of the studies into treatment optimization.